CoChat

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

Open access

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

Hormone receptor (HR) + breast cancer (BC) causes most BC-related deaths, calling for improved therapeutic approaches. Despite expectations, immune checkpoint blockers (ICBs) are poorly active in patients with HR + BC, in part reflecting the lack of preclinical models that recapitulate disease progression in immunocompetent hosts. We demonstrate that mammary tumors driven by medroxyprogesterone acetate (M) and 7,12-dimethylbenz[a]anthracene (D) recapitulate several key features of human luminal B HR + HER2 − BC, including limited immune infiltration and poor sensitivity to ICBs. M/D-driven oncogenesis is accelerated by immune defects, demonstrating that M/D-driven tumors are under immunosurveillance. Safe nutritional measures including nicotinamide (NAM) supplementation efficiently delay M/D-driven oncogenesis by reactivating immunosurveillance. NAM also mediates immunotherapeutic effects against established M/D-driven and transplantable BC, largely reflecting increased type I interferon secretion by malignant cells and direct stimulation of immune effector cells. Our findings identify NAM as a potential strategy for the prevention and treatment of HR + BC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-17644-0

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 M/D-driven tumors recapitulate key features of human HR+ breast cancer. a Schedule of oncogenic challenges for the induction of M/D-driven tumors and representative images of M/D-driven tumors established in WT C57BL/6 mice. Scale bar = 1 cm. b Tumor-free survival (TFS) and time-to-death (TTD) in WT C57BL/6 mice subjected to M/D-driven oncogenesis. Number of mice is reported. c Representative histology of M/D-driven tumors as compared to human HR+ breast cancers. Scale bar = 50 µm. d Probeset distribution comparing the transcriptomic profile of 6 M/D-driven mammary tumors established in C57BL/6 mice with that of human breast cancers from the TCGA public database. Probability of molecular subtyping is reported for each mouse tumors. e, f TFS and overall survival (OS) of WT C57BL/6 mice and C57BL/6 bearing ER mutations that cause nuclear exclusion (e) or nuclear accumulation (f) subjected to M/D-driven oncogenesis. Number of mice, hazard ratio (HR) and p values (two-sided log-rank) are reported. g TFS and OS of WT C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions or along with tamoxifen administration in the drinking water. Number of mice, HR and p values (two-sided log-rank) are reported. h. Non-supervised hierarchical clustering of the transcriptomic profile of M/D-driven tumors established in WT C57BL/6 mice (n = 6), mammary glands exposed to M/D but not developing tumors (n = 6) and M/D-naïve mammary glands (n = 6). Gene Ontology analysis, fold change (FC) and adjusted, two-sided p values are reported. Red, upregulation. Yellow, downregulation. i Relative amount of CD3+, CD8+, CD4+ and CD25+FOXP3+ cells infiltrating M/D-driven tumors in C57BL/6 mice vs syngeneic M/D-naïve mammary glands. Results are means ± SEM plus individual data points. Number of mice and p values (unpaired, two-sided Student’s t, as compared to M/D-naïve mammary glands) are reported.
Fig. 1 M/D-driven tumors recapitulate key features of human HR+ breast cancer. a Schedule of oncogenic challenges for the induction of M/D-driven tumors and representative images of M/D-driven tumors established in WT C57BL/6 mice. Scale bar = 1 cm. b Tumor-free survival (TFS) and time-to-death (TTD) in WT C57BL/6 mice subjected to M/D-driven oncogenesis. Number of mice is reported. c Representative histology of M/D-driven tumors as compared to human HR+ breast cancers. Scale bar = 50 µm. d Probeset distribution comparing the transcriptomic profile of 6 M/D-driven mammary tumors established in C57BL/6 mice with that of human breast cancers from the TCGA public database. Probability of molecular subtyping is reported for each mouse tumors. e, f TFS and overall survival (OS) of WT C57BL/6 mice and C57BL/6 bearing ER mutations that cause nuclear exclusion (e) or nuclear accumulation (f) subjected to M/D-driven oncogenesis. Number of mice, hazard ratio (HR) and p values (two-sided log-rank) are reported. g TFS and OS of WT C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions or along with tamoxifen administration in the drinking water. Number of mice, HR and p values (two-sided log-rank) are reported. h. Non-supervised hierarchical clustering of the transcriptomic profile of M/D-driven tumors established in WT C57BL/6 mice (n = 6), mammary glands exposed to M/D but not developing tumors (n = 6) and M/D-naïve mammary glands (n = 6). Gene Ontology analysis, fold change (FC) and adjusted, two-sided p values are reported. Red, upregulation. Yellow, downregulation. i Relative amount of CD3+, CD8+, CD4+ and CD25+FOXP3+ cells infiltrating M/D-driven tumors in C57BL/6 mice vs syngeneic M/D-naïve mammary glands. Results are means ± SEM plus individual data points. Number of mice and p values (unpaired, two-sided Student’s t, as compared to M/D-naïve mammary glands) are reported.CC BY · PubMed Central
Fig. 2 M/D-driven oncogenesis is under immunosurveillance by NK cells. a, b Tumor-free survival (TFS), overall survival (OS) and time-to-death (TTD) of WT C57BL/6 mice (a, b) and Rag2−/−Il2rg−/− mice (a) or Ifng−/− mice (b) subjected to M/D-driven oncogenesis. Number of mice, hazard ratio (HR) and p values (two-sided log-rank) are reported. c–e. Variations in TFS (c), OS (d) and TTD (e) imposed to M/D-driven oncogenesis in mice by the indicated genotype or immunomodulatory interventions. Results are means ± SEM plus individual data points. Number of mice, HR and p values (two-sided log-rank and one way-ANOVA plus Fisher LSD, calculated with respect to individual control experiments) are reported. Green dots indicate mice that were free of disease (c) and alive (d) at the end of the experiment. f–h TFS and OS of WT C57BL/6 (f–h) mice and Rag2−/− BALB/c mice (f), C57BL/6 mice receiving NKG2D-depleting antibodies (g), or C57BL/6 mice receiving CD4- and CD8-depleting antibodies (h). Number of mice, HR and p values (two-sided log-rank) are reported.
Fig. 2 M/D-driven oncogenesis is under immunosurveillance by NK cells. a, b Tumor-free survival (TFS), overall survival (OS) and time-to-death (TTD) of WT C57BL/6 mice (a, b) and Rag2−/−Il2rg−/− mice (a) or Ifng−/− mice (b) subjected to M/D-driven oncogenesis. Number of mice, hazard ratio (HR) and p values (two-sided log-rank) are reported. c–e. Variations in TFS (c), OS (d) and TTD (e) imposed to M/D-driven oncogenesis in mice by the indicated genotype or immunomodulatory interventions. Results are means ± SEM plus individual data points. Number of mice, HR and p values (two-sided log-rank and one way-ANOVA plus Fisher LSD, calculated with respect to individual control experiments) are reported. Green dots indicate mice that were free of disease (c) and alive (d) at the end of the experiment. f–h TFS and OS of WT C57BL/6 (f–h) mice and Rag2−/− BALB/c mice (f), C57BL/6 mice receiving NKG2D-depleting antibodies (g), or C57BL/6 mice receiving CD4- and CD8-depleting antibodies (h). Number of mice, HR and p values (two-sided log-rank) are reported.CC BY · PubMed Central
Fig. 3 M/D-driven tumors are poorly immunoedited by T cells and sensitive to vaccination. a–d Growth of cell lines established from M/D-driven tumors (herein called mammary gland tumors, MGTs) developing in immunocompetent (IC) mice upon subcutaneous (a, c) or orthotopic (b, d) implantation in Rag2−/− (a, b) or IC C57BL/6 mice (c, d) optionally bearing an MPA-releasing pellet. Individual curves and tumor incidence are reported. e Growth of MGTs upon subcutaneous implantation in IC C57BL/6 mice receiving DMBA alone or in the context of an MPA-releasing pellet. Individual curves for all tumors and subcutaneous tumor incidence are reported. Boxed curves refer to endogenous tumors caused by DMBA alone or MPA plus DMBA. f Growth of MGTs established from M/D-driven tumors developing in immunodeficient (ID) Rag2−/− mice upon subcutaneous implantation in IC C57BL/6 mice. Individual curves and global tumor incidence are reported. g Tumor-free survival (TFS), overall survival (OS) and time-to-death (TTD) of WT C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions or upon vaccination with cell lines established from M/D-driven tumors developing in IC or ID mice and treated with mitoxantrone (MTX) in vitro. Number of mice, hazard ratio (HR) and p values (two-sided log-rank, as compared to non-vaccinated mice) are reported. h TFS, OS, and TTD of WT C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions or upon vaccination with mouse mammary gland organoids (MMGOs) optionally killed in vitro by exposure to radiation therapy (RT) in a single dose of 20 Gy. Number of mice, HR and p values (two-sided log-rank, as compared to non-vaccinated mice) are reported. Please note that part of these results (control conditions) are also depicted in (i). i TFS, OS, and TTD of WT C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions or upon vaccination with MMGOs killed in vitro by mitoxantrone (MTX) administration in the optional context of ANXA1 neutralization. Number of mice, HR and p values (two-sided log-rank, as compared to non-vaccinated mice) are reported. Please note that part of these results (control conditions) are also depicted in (h).
Fig. 3 M/D-driven tumors are poorly immunoedited by T cells and sensitive to vaccination. a–d Growth of cell lines established from M/D-driven tumors (herein called mammary gland tumors, MGTs) developing in immunocompetent (IC) mice upon subcutaneous (a, c) or orthotopic (b, d) implantation in Rag2−/− (a, b) or IC C57BL/6 mice (c, d) optionally bearing an MPA-releasing pellet. Individual curves and tumor incidence are reported. e Growth of MGTs upon subcutaneous implantation in IC C57BL/6 mice receiving DMBA alone or in the context of an MPA-releasing pellet. Individual curves for all tumors and subcutaneous tumor incidence are reported. Boxed curves refer to endogenous tumors caused by DMBA alone or MPA plus DMBA. f Growth of MGTs established from M/D-driven tumors developing in immunodeficient (ID) Rag2−/− mice upon subcutaneous implantation in IC C57BL/6 mice. Individual curves and global tumor incidence are reported. g Tumor-free survival (TFS), overall survival (OS) and time-to-death (TTD) of WT C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions or upon vaccination with cell lines established from M/D-driven tumors developing in IC or ID mice and treated with mitoxantrone (MTX) in vitro. Number of mice, hazard ratio (HR) and p values (two-sided log-rank, as compared to non-vaccinated mice) are reported. h TFS, OS, and TTD of WT C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions or upon vaccination with mouse mammary gland organoids (MMGOs) optionally killed in vitro by exposure to radiation therapy (RT) in a single dose of 20 Gy. Number of mice, HR and p values (two-sided log-rank, as compared to non-vaccinated mice) are reported. Please note that part of these results (control conditions) are also depicted in (i). i TFS, OS, and TTD of WT C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions or upon vaccination with MMGOs killed in vitro by mitoxantrone (MTX) administration in the optional context of ANXA1 neutralization. Number of mice, HR and p values (two-sided log-rank, as compared to non-vaccinated mice) are reported. Please note that part of these results (control conditions) are also depicted in (h).CC BY · PubMed Central
Fig. 4 Safe nutritional interventions delay M/D-driven oncogenesis. a, b Tumor-free survival (TFS), overall survival (OS) and time-to-death (TTD) of C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions (a, b) or in the context of weekly 24-h-fasting episodes (a) or NAM supplementation with the drinking water (b). Number of mice, hazard ratio (HR) and p values (two-sided log-rank) are reported. c–e Variations in TFS (c), OS (d) and TTD (e) imposed to M/D-driven oncogenesis in C57BL/6 mice by the indicated nutritional interventions. Results are means ± SEM plus individual data points. Number of mice, HR and p values (two-sided log-rank and one way-ANOVA plus Fisher LSD, calculated with respect to individual control experiments) are reported. Green dots indicate mice that were free of disease (c) and alive (d) at the end of the experiment. HFD high-fat diet, HSD high sucrose diet, NR nicotinamide riboside.
Fig. 4 Safe nutritional interventions delay M/D-driven oncogenesis. a, b Tumor-free survival (TFS), overall survival (OS) and time-to-death (TTD) of C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions (a, b) or in the context of weekly 24-h-fasting episodes (a) or NAM supplementation with the drinking water (b). Number of mice, hazard ratio (HR) and p values (two-sided log-rank) are reported. c–e Variations in TFS (c), OS (d) and TTD (e) imposed to M/D-driven oncogenesis in C57BL/6 mice by the indicated nutritional interventions. Results are means ± SEM plus individual data points. Number of mice, HR and p values (two-sided log-rank and one way-ANOVA plus Fisher LSD, calculated with respect to individual control experiments) are reported. Green dots indicate mice that were free of disease (c) and alive (d) at the end of the experiment. HFD high-fat diet, HSD high sucrose diet, NR nicotinamide riboside.CC BY · PubMed Central
Fig. 5 NAM mediates chemopreventive effects by boosting immunosurveillance. a–c Tumor-free survival (TFS) and overall survival (OS) of Rag2−/−Il2rg−/− mice subjected to M/D-driven oncogenesis in control conditions (a–c) or along with NAM (a), pyridoxine (b) or calcitriol (c) supplementation. Number of mice, hazard ratio (HR) and p values (two-sided log-rank) are reported. d–g TFS and OS of Rag2−/− mice (d), C57BL/6 mice receiving CD4- and CD8α-depleting antibodies (e), C57BL/6 mice receiving an IFNG-neutralizing antibody (f), and Ifnar1−/− mice (g) subjected to M/D-driven oncogenesis in control conditions or along with NAM supplementation with the drinking water. Number of mice, HR and p values (two-sided log-rank) are reported. h, i Gene sets enriched in the spleen (h) and lymph nodes (i) of tumor-naive C57BL/6 mice receiving NAM supplementation with the drinking water for 1, 3 or 14 days. Adjusted, two-sided p values for enrichment are reported.
Fig. 5 NAM mediates chemopreventive effects by boosting immunosurveillance. a–c Tumor-free survival (TFS) and overall survival (OS) of Rag2−/−Il2rg−/− mice subjected to M/D-driven oncogenesis in control conditions (a–c) or along with NAM (a), pyridoxine (b) or calcitriol (c) supplementation. Number of mice, hazard ratio (HR) and p values (two-sided log-rank) are reported. d–g TFS and OS of Rag2−/− mice (d), C57BL/6 mice receiving CD4- and CD8α-depleting antibodies (e), C57BL/6 mice receiving an IFNG-neutralizing antibody (f), and Ifnar1−/− mice (g) subjected to M/D-driven oncogenesis in control conditions or along with NAM supplementation with the drinking water. Number of mice, HR and p values (two-sided log-rank) are reported. h, i Gene sets enriched in the spleen (h) and lymph nodes (i) of tumor-naive C57BL/6 mice receiving NAM supplementation with the drinking water for 1, 3 or 14 days. Adjusted, two-sided p values for enrichment are reported.CC BY · PubMed Central
Fig. 6 NAM mediates immunotherapeutic effects on established BCs. a Time-to-death (TTD) of C57BL/6 mice subjected to M/D-driven carcinogenesis in control conditions or in the context of NAM supplementation with the drinking water, either from MPA pellet implantation (prevention) or tumor detection (treatment). Number of mice, hazard ratio (HR) and p values (two-sided log-rank) are reported. b Tumor growth and overall survival (OS) in C57BL/6 mice bearing established M/D-driven tumors that were maintained in control conditions or subjected to NAM supplementation with the drinking water. Tumor growth results are means ± SEM. Number of mice, HR and p values (two-way ANOVA corrected for row (time) and column (treatment) factors for tumor growth and two-sided log-rank for OS) are reported. c Non-supervised hierarchical clustering of genes differentially expressed in untreated (n = 4) vs NAM-treated (n = 4) M/D-driven tumors. Top upregulated genes, fold change (FC) and adjusted, two-sided p values are reported. Gene Ontology analysis and adjusted, two-sided p values for enrichment are indicated. d Comparison of private vs shared transcriptional changes induced by NAM treatment in M/D-driven tumors vs AT3 tumors established in C57BL/6 mice. The list of genes upregulated by NAM in both models is provided. See also Supplementary Fig. 3g. e Ingenuity Pathway Analysis of genes upregulated by NAM in both M/D-driven tumors AT3 tumors established in C57BL/6 mice. f Immune infiltration of AT3 tumors established in C57BL/6 mice that were maintained in control conditions or received NAM supplementation with the drinking water (starting at tumor detection) for 10 days. Results are means ± SEM plus individual data points. Number of mice and p values (one way-ANOVA plus Fisher LSD) are reported.
Fig. 6 NAM mediates immunotherapeutic effects on established BCs. a Time-to-death (TTD) of C57BL/6 mice subjected to M/D-driven carcinogenesis in control conditions or in the context of NAM supplementation with the drinking water, either from MPA pellet implantation (prevention) or tumor detection (treatment). Number of mice, hazard ratio (HR) and p values (two-sided log-rank) are reported. b Tumor growth and overall survival (OS) in C57BL/6 mice bearing established M/D-driven tumors that were maintained in control conditions or subjected to NAM supplementation with the drinking water. Tumor growth results are means ± SEM. Number of mice, HR and p values (two-way ANOVA corrected for row (time) and column (treatment) factors for tumor growth and two-sided log-rank for OS) are reported. c Non-supervised hierarchical clustering of genes differentially expressed in untreated (n = 4) vs NAM-treated (n = 4) M/D-driven tumors. Top upregulated genes, fold change (FC) and adjusted, two-sided p values are reported. Gene Ontology analysis and adjusted, two-sided p values for enrichment are indicated. d Comparison of private vs shared transcriptional changes induced by NAM treatment in M/D-driven tumors vs AT3 tumors established in C57BL/6 mice. The list of genes upregulated by NAM in both models is provided. See also Supplementary Fig. 3g. e Ingenuity Pathway Analysis of genes upregulated by NAM in both M/D-driven tumors AT3 tumors established in C57BL/6 mice. f Immune infiltration of AT3 tumors established in C57BL/6 mice that were maintained in control conditions or received NAM supplementation with the drinking water (starting at tumor detection) for 10 days. Results are means ± SEM plus individual data points. Number of mice and p values (one way-ANOVA plus Fisher LSD) are reported.CC BY · PubMed Central
Fig. 7 The therapeutic effects of NAM depend on T cells and immune signaling. a–c Tumor growth and overall survival (OS) in C57BL/6 mice bearing established M/D-driven tumors that were maintained in control conditions (a–c) or subjected to NAM supplementation with the drinking water alone (a–c), or in the context of CD4+ and CD8+ T cell co-depletion (a), NK cell depletion (b), or IFNG neutralization (c). Tumor growth results are means ± SEM. Number of mice, hazard ratio (HR) and p values (two-way ANOVA corrected for row (time) and column (treatment) factors for tumor growth and two-sided log-rank for OS). Please note that NAM-treated tumors (red curves) in (a–c) are from the same experiment, also depicted in (d). d, e Tumor growth and OS in C57BL/6 (d) or BALB/c (e) mice bearing established M/D-driven (d) or TSA (e) tumors that were maintained in control conditions or subjected to NAM supplementation with the drinking water or systemic PD-1 blockage, alone or in combination. Tumor growth results are means ± SEM. Number of mice, hazard ratio (HR) and p values (two-way ANOVA corrected for row (time) and column (treatment) factors for tumor growth and two-sided log-rank for OS). Please note that NAM-treated tumors (red curves) in (d) are from the same experiment depicted in (a–c).
Fig. 7 The therapeutic effects of NAM depend on T cells and immune signaling. a–c Tumor growth and overall survival (OS) in C57BL/6 mice bearing established M/D-driven tumors that were maintained in control conditions (a–c) or subjected to NAM supplementation with the drinking water alone (a–c), or in the context of CD4+ and CD8+ T cell co-depletion (a), NK cell depletion (b), or IFNG neutralization (c). Tumor growth results are means ± SEM. Number of mice, hazard ratio (HR) and p values (two-way ANOVA corrected for row (time) and column (treatment) factors for tumor growth and two-sided log-rank for OS). Please note that NAM-treated tumors (red curves) in (a–c) are from the same experiment, also depicted in (d). d, e Tumor growth and OS in C57BL/6 (d) or BALB/c (e) mice bearing established M/D-driven (d) or TSA (e) tumors that were maintained in control conditions or subjected to NAM supplementation with the drinking water or systemic PD-1 blockage, alone or in combination. Tumor growth results are means ± SEM. Number of mice, hazard ratio (HR) and p values (two-way ANOVA corrected for row (time) and column (treatment) factors for tumor growth and two-sided log-rank for OS). Please note that NAM-treated tumors (red curves) in (d) are from the same experiment depicted in (a–c).CC BY · PubMed Central
Fig. 8 NAM-treated tumors exhibit improved antigen presentation and superior cytotoxic functions. a tSNE plots of untreated and NAM-treated TSA tumors. Number of cells in each of the main four populations is reported. b Differential expression of genes involved in immune regulation in CD45+ cells isolated from untreated vs NAM-treated TSA tumors. Results are mean ± SEM plus individual data points. Number of cells independently analyzed for each gene is reported in (a), p values (two-sided Wilcoxon test) are indicated. See also Supplementary Data 1. c, d Percentage of IFNG+ and IFNG+GZMB+ amongst CD8+ T cells (c) and CD56+ NK cells (d) from peripheral blood mononuclear cells (PBMCs) of healthy donors subjected to non-specific activation overnight in the presence of the indicated concentrations of NAM. Results are means ± SEM plus individual data points. Number of biologically independent samples and p values (one way-ANOVA plus Fisher LSD, as compared to untreated cells) are reported. e Relative expression levels of Ifnb1 and Ccl2 in TSA cells cultured in control conditions or exposed to the indicated concentrations of NAM for 48 h. Results are means ± SEM plus individual data points. Number of biologically independent samples and p values (one way-ANOVA plus Fisher LSD, as compared to untreated cells) are reported.
Fig. 8 NAM-treated tumors exhibit improved antigen presentation and superior cytotoxic functions. a tSNE plots of untreated and NAM-treated TSA tumors. Number of cells in each of the main four populations is reported. b Differential expression of genes involved in immune regulation in CD45+ cells isolated from untreated vs NAM-treated TSA tumors. Results are mean ± SEM plus individual data points. Number of cells independently analyzed for each gene is reported in (a), p values (two-sided Wilcoxon test) are indicated. See also Supplementary Data 1. c, d Percentage of IFNG+ and IFNG+GZMB+ amongst CD8+ T cells (c) and CD56+ NK cells (d) from peripheral blood mononuclear cells (PBMCs) of healthy donors subjected to non-specific activation overnight in the presence of the indicated concentrations of NAM. Results are means ± SEM plus individual data points. Number of biologically independent samples and p values (one way-ANOVA plus Fisher LSD, as compared to untreated cells) are reported. e Relative expression levels of Ifnb1 and Ccl2 in TSA cells cultured in control conditions or exposed to the indicated concentrations of NAM for 48 h. Results are means ± SEM plus individual data points. Number of biologically independent samples and p values (one way-ANOVA plus Fisher LSD, as compared to untreated cells) are reported.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 72 references

Research works printed but not linked: 1

  1. Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. Preprint at https://www.biorxiv.org/content/10.1101/060012v2 (2019). · doi:10.1101/060012v2

Cited by

See all 138

Metadata

Authors
Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., Aranda, F., Durand, S., Boissonnas, A., Fucikova, J., Senovilla, L., Enot, D., Hensler, M., Kremer, M., Stoll, G., Hu, Y., Massa, C., Formenti, S. C., Seliger, B., Elemento, O., Spisek, R., André, F., Zitvogel, L., Delaloge, S., Kroemer, G., & Galluzzi, L.
Affiliations
  • Inserm (FR)
  • Université Paris-Sud (FR)
  • Weill Cornell Medicine (US)
  • Centre National de la Recherche Scientifique (FR)
  • Charles University (CZ)
  • Sotio (Czechia) (CZ)
  • Martin Luther University Halle-Wittenberg (DE)
  • Institut Gustave Roussy (FR)
  • Karolinska University Hospital (SE)
  • Université Paris Cité (FR)
Corresponding author
  • Kroemer, Guido
  • Galluzzi, Lorenzo
Venue
Nature Communications
Published
2020-07-30
Volume
11
Issue
1
Pages
3819-3819
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3045997924
Cited by
138
References
71
Citations by year
2026: 12 · 2025: 23 · 2024: 19 · 2023: 24 · 2022: 25 · 2021: 28 · 2020: 7
FWCI
7.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
U.S. Department of Defense (BC180476P1)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
hormone receptor-positive breast cancer, luminal B, immune surveillance, medroxyprogesterone acetate, 7,12-dimethylbenz(a)anthracene, mammary tumor model, nicotinamide, type I interferon, immunotherapy, cancer prevention, immune cell infiltration, immunocompetent model
MeSH terms
Animals, Breast Neoplasms, Female, Humans, Immunotherapy, Interferon Type I, Mammary Neoplasms, Experimental, Mice, Inbred BALB C, Mice, Inbred C57BL, Niacinamide, 9,10-Dimethyl-1,2-benzanthracene, Survival Analysis, Medroxyprogesterone Acetate, Mice, Knockout, Disease Progression, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. https://app.cochat.ai/papers/10.1038/s41467-020-17644-0
The paper
Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., Aranda, F., Durand, S., Boissonnas, A., Fucikova, J., Senovilla, L., Enot, D., Hensler, M., Kremer, M., Stoll, G., . . . Galluzzi, L. (2020). Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature Communications. https://doi.org/10.1038/s41467-020-17644-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.